Last reviewed · How we verify
EPI-003
At a glance
| Generic name | EPI-003 |
|---|---|
| Sponsor | Epigenic Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B (EARLY_PHASE1)
- Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EPI-003 CI brief — competitive landscape report
- EPI-003 updates RSS · CI watch RSS
- Epigenic Therapeutics, Inc portfolio CI